49743-87-5 Usage
General Description
4'-HYDROXYMETHYL-BIPHENYL-4-CARBOXYLIC ACID is a chemical compound with the molecular formula C14H12O3. It is a derivative of biphenyl and carboxylic acid, and its structure consists of a biphenyl core with a hydroxymethyl group and a carboxylic acid group attached to the 4' position. 4'-HYDROXYMETHYL-BIPHENYL-4-CARBOXYLIC ACID has potential applications in the field of organic synthesis and pharmaceutical research due to its unique structural properties. Its synthesis and characterization could lead to the development of novel materials and pharmaceuticals with important biological activities. Additionally, 4'-HYDROXYMETHYL-BIPHENYL-4-CARBOXYLIC ACID could also serve as a building block in the synthesis of other complex organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 49743-87-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,9,7,4 and 3 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 49743-87:
(7*4)+(6*9)+(5*7)+(4*4)+(3*3)+(2*8)+(1*7)=165
165 % 10 = 5
So 49743-87-5 is a valid CAS Registry Number.
49743-87-5Relevant articles and documents
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR
Petros, Andrew M.,Huth, Jeffrey R.,Oost, Thorsten,Park, Cheol-Min,Ding, Hong,Wang, Xilu,Zhang, Haichao,Nimmer, Paul,Mendoza, Renaldo,Sun, Chaohong,MacK, Jamey,Walter, Karl,Dorwin, Sarah,Gramling, Emily,Ladror, Uri,Rosenberg, Saul H.,Elmore, Steven W.,Fesik, Stephen W.,Hajduk, Philip J.
scheme or table, p. 6587 - 6591 (2010/12/20)
The Bcl-2 family of proteins plays a major role in the regulation of apoptosis, or programmed cell death. Overexpression of the anti-apoptotic members of this family (Bcl-2, Bcl-xL, and Mcl-1) can render cancer cells resistant to chemotherapeutic agents and therefore these proteins are important targets for the development of new anti-cancer agents. Here we describe the discovery of a potent, highly selective, Bcl-2 inhibitor using SAR by NMR and structure-based drug design which could serve as a starting point for the development of a Bcl-2 selective anti-cancer agent. Such an agent would potentially overcome the Bcl-xL mediated thrombocytopenia observed with ABT-263.
